Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VLA15
- Development stage
- Phase 3
- Lead developer
- Pfizer
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
VLA15 is an investigational multivalent recombinant protein subunit vaccine developed for the prevention of Lyme disease. It targets the outer surface protein A (OspA) of Borrelia burgdorferi sensu lato species—the bacteria responsible for causing Lyme disease. OspA is expressed by the bacteria when present in a tick; blocking OspA inhibits the bacterium’s ability to leave the tick and infect humans. VLA15 covers six of the most prevalent OspA serotypes found in North America and Europe. The vaccine is alum-adjuvanted and administered intramuscularly. Clinical trials have demonstrated strong immunogenicity and a favorable safety profile across adults and children aged 5 years or older. As of 2024, it is in Phase 3 clinical development with no approved human vaccines for Lyme disease currently available[1][2][3][4][5][6][8].
- Other names
- Borrelia vaccine - GlaxoSmithKline/ValnevaLyme borreliosis vaccine - GlaxoSmithKline/ValnevaLyme-borreliosis-vaccine-ValnevaLyme-disease-vaccine-GlaxoSmithKline/ValnevaLyme-disease-vaccine-Valneva
02
Targets
OspA (Outer surface protein A)
Beyond the preview
Go deeper on VLA15.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VLA15.